Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

CGON

CG Oncology (CGON)

CG Oncology Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:CGON
DatumZeitQuelleÜberschriftSymbolFirma
24/05/202414h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CGONCG Oncology Inc
24/05/202414h00GlobeNewswire Inc.CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual MeetingNASDAQ:CGONCG Oncology Inc
09/05/202414h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CGONCG Oncology Inc
09/05/202414h00GlobeNewswire Inc.CG Oncology Reports First Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:CGONCG Oncology Inc
09/05/202412h07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CGONCG Oncology Inc
03/05/202417h23GlobeNewswire Inc.Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder CancerNASDAQ:CGONCG Oncology Inc
26/04/202414h00GlobeNewswire Inc.CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024NASDAQ:CGONCG Oncology Inc
24/04/202416h00GlobeNewswire Inc.CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024NASDAQ:CGONCG Oncology Inc
28/03/202413h00GlobeNewswire Inc.CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual MeetingNASDAQ:CGONCG Oncology Inc
27/02/202414h00GlobeNewswire Inc.CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder CancerNASDAQ:CGONCG Oncology Inc
30/01/202413h00Business WireCG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:CGONCG Oncology Inc
 Showing the most relevant articles for your search:NASDAQ:CGON